New Insights Into Prostate Cancer Care

Dr. Ashwin Singh Parihar sits down with to discuss how post-therapy Lutetium 177 PSMA SPECT CT may help predict overall survival in patients with metastatic castration resistant prostate cancer and shape future treatment decisions. Drawing from the ENZAPI trial, they explore quantitative imaging, treatment response assessment, adaptive dosing strategies, and the growing role of theranostics in precision oncology.   177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Ayati et al. Radiology 2026; 319(1):e252672.